{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T15:40:43Z","timestamp":1789486843901,"version":"build-2803163510"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Juvenile generalized myasthenia gravis (MG) management aims to control symptoms while minimizing corticosteroid-related toxicity. However, large-scale evidence on real-world pediatric treatment patterns remains limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort study using a large Japanese hospital-based claims database (Medical Data Vision). We identified patients aged 0\u201317\u202fyears with juvenile generalized MG between April 2008 and November 2024. We summarized the use of cholinesterase inhibitors, oral corticosteroids, immunosuppressants, and intensive treatments (plasma exchange, intravenous immunoglobulin [IVIg], or high-dose steroid pulse therapy) during the one-year follow-up period after the first confirmed MG diagnosis recorded in the database. We also compared patient characteristics and treatment patterns by age group (children: 0\u20139\u202fyears vs. adolescents: 10\u201317\u202fyears).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified 261 patients with juvenile generalized MG, including 125 children and 136 adolescents cases. Cholinesterase inhibitors were the most frequently used medication (69.3% [181\/261]). Oral corticosteroids were commonly used (65.9% [172\/261]), whereas immunosuppressant use was limited; only 89\/261 (34.1%) received tacrolimus. Among the 217 patients with complete one-year follow-up data, 146 received corticosteroid. The mean daily corticosteroid dose, calculated as the annual cumulative corticosteroid dose divided by 365\u202fdays, was 8.7\u202fmg\/day (SD 7.1) (children: 6.2\u202fmg\/day [SD 4.1]; adolescents: 11.4\u202fmg\/day [SD 8.6]). Among 261 generalized MG patients, 52 (19.9%) received intensive treatments, with a higher proportion in adolescents than children (25.7% [35\/136] vs. 13.6% [17\/125]). IVIg was the most common intensive treatment (13.4% [35\/261]), followed by steroid pulse therapy (10.3% [27\/261]) and plasma exchange (3.8% [10\/261]). Adolescent generalized MG had higher intensive care unit hospitalization rates than child generalized MG (8.8% [12\/136] vs. 0.8% [1\/125]), and all thymectomies occurred in adolescent patients (8.1% [11\/136] vs. 0% [0\/125]).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In Japanese real-world practice, about one in five children with generalized MG required intensive treatments, particularly among adolescents, while steroid-sparing immunosuppression was used in only one-third. These findings support close monitoring of adolescent generalized MG and highlight opportunities to optimize steroid-sparing management in juvenile generalized MG.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2026.1877931","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T13:25:14Z","timestamp":1789478714000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment patterns, intensive treatment, and hospitalization-related burden of juvenile generalized myasthenia gravis in Japan: a retrospective cohort study using a hospital-based claims database"],"prefix":"10.3389","volume":"17","author":[{"given":"Keiko","family":"Ishigaki","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Tokyo Women\u2019s Medical University School of Medicine","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Horio","sequence":"additional","affiliation":[{"name":"Medical Affairs Division, Johnson & Johnson","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahide","family":"Kitamura","sequence":"additional","affiliation":[{"name":"Medical Affairs Division, Johnson & Johnson","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Saga","sequence":"additional","affiliation":[{"name":"Medical Affairs Division, Johnson & Johnson","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/bs.irn.2025.04.028","article-title":"Epidemiology of myasthenia gravis","volume":"182","author":"Gilhus","year":"2025","journal-title":"Int Rev Neurobiol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"834212","DOI":"10.3389\/fneur.2022.834212","article-title":"The epidemiology and phenotypes of ocular manifestations in childhood and juvenile myasthenia gravis: a review","volume":"13","author":"Heckmann","year":"2022","journal-title":"Front Neurol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jns.2011.03.004","article-title":"Characteristics of myasthenia gravis according to onset-age: Japanese nationwide survey","volume":"305","author":"Murai","year":"2011","journal-title":"J Neurol Sci"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1007\/s40120-025-00750-w","article-title":"Incidence and prevalence of juvenile myasthenia gravis in the United States between 2010 and 2020: analysis of two claims databases","volume":"14","author":"Zhou","year":"2025","journal-title":"Neurol Ther"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"404101","DOI":"10.4061\/2011\/404101","article-title":"Juvenile myasthenia gravis: a paediatric perspective","volume":"2011","author":"Finnis","year":"2011","journal-title":"Autoimmune Dis"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"743","DOI":"10.3389\/fneur.2020.00743","article-title":"Management of juvenile myasthenia gravis","volume":"11","author":"O\u2019Connell","year":"2020","journal-title":"Front Neurol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1119294","DOI":"10.3389\/fneur.2023.1119294","article-title":"Outcome and clinical features in juvenile myasthenia gravis: a systematic review and meta-analysis","volume":"14","author":"Lin","year":"2023","journal-title":"Front Neurol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","article-title":"International consensus guidance for Management of Myasthenia Gravis: 2020 update","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"17562864231213240","DOI":"10.1177\/17562864231213240","article-title":"Guideline for the management of myasthenic syndromes","volume":"16","author":"Wiendl","year":"2023","journal-title":"Ther Adv Neurol Disord"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s40272-024-00649-3","article-title":"Targeted treatments for myasthenia gravis in children and adolescents","volume":"26","author":"Ramdas","year":"2024","journal-title":"Paediatr Drugs"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1002\/mus.24213","article-title":"Health-related quality-of-life and treatment targets in myasthenia gravis","volume":"50","author":"Utsugisawa","year":"2014","journal-title":"Muscle Nerve"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"868","DOI":"10.3389\/fneur.2020.00868","article-title":"Reappraisal of Oral steroid therapy for myasthenia gravis","volume":"11","author":"Imai","year":"2020","journal-title":"Front Neurol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.pediatrneurol.2017.08.014","article-title":"Tacrolimus improves symptoms of children with myasthenia gravis refractory to prednisone","volume":"77","author":"Liu","year":"2017","journal-title":"Pediatr Neurol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1080\/01658100701648645","article-title":"Childhood myasthenia gravis in Japan\u2014clinical analysis of 184 cases at Segawa neurological Clinic for Children for 30 years","volume":"31","author":"Nomura","year":"2007","journal-title":"Neuro-Ophthalmol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"e939","DOI":"10.1542\/peds.2013-0814","article-title":"Clinical characteristics of pediatric myasthenia: a surveillance study","volume":"132","author":"VanderPluym","year":"2013","journal-title":"Pediatrics"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s12883-022-02692-4","article-title":"A retrospective longitudinal cohort study of the clinical burden in myasthenia gravis","volume":"22","author":"Harris","year":"2022","journal-title":"BMC Neurol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"e213736","DOI":"10.1212\/WNL.0000000000213736","article-title":"Treatment patterns and disease burden of juvenile myasthenia gravis in the United States","volume":"105","author":"Zhou","year":"2025","journal-title":"Neurology"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"58","DOI":"10.4103\/aian.aian_386_24","article-title":"Outcome predictors of generalized myasthenia gravis: a prospective observational study","volume":"28","author":"Kalita","year":"2025","journal-title":"Ann Indian Acad Neurol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"e001000","DOI":"10.1136\/bmjno-2024-001000","article-title":"Epidemiology and 10-year clinical care of juvenile myasthenia gravis in England: a retrospective cohort study","volume":"7","author":"Abbasi","year":"2025","journal-title":"BMJ Neurol Open"},{"key":"ref20","author":"Liu","year":"2026"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1186\/s12967-026-07925-5","article-title":"Efficacy and safety of immunosuppressants and immunomodulators in juvenile myasthenia gravis: a systematic review and meta-analysis","volume":"24","author":"Zhong","year":"2026","journal-title":"J Transl Med"},{"key":"ref22","volume-title":"Guidelines for the Diagnosis and Treatment of Myasthenia gravis and Lambert\u2013Eaton Myasthenic Syndrome 2022","year":"2022"},{"key":"ref23","year":"2011"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1214041","DOI":"10.3389\/fneur.2023.1214041","article-title":"Diagnosis and therapy of myasthenia gravis-the patients\u2019 perspective: a cross-sectional study","volume":"14","author":"Sobierajski","year":"2023","journal-title":"Front Neurol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"e215767","DOI":"10.1001\/jamapediatrics.2021.5767","article-title":"Assessment of long-term psychological outcomes after pediatric intensive care unit admission: a systematic review and Meta-analysis","volume":"176","author":"Ko","year":"2022","journal-title":"JAMA Pediatr"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"19275","DOI":"10.1038\/s41598-022-22078-3","article-title":"Mental health in myasthenia gravis patients and its impact on caregiver burden","volume":"12","author":"Marbin","year":"2022","journal-title":"Sci Rep"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1877931\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T13:25:16Z","timestamp":1789478716000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1877931\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":26,"alternative-id":["10.3389\/fneur.2026.1877931"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2026.1877931","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]},"article-number":"1877931"}}